Clinical Trial Update: Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing apixaban with vitamin K antagonists in patients with atrial fibrillation and end-stage kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• End-stage Kidney Disease

Drugs mentioned

• Apixaban (apixaban)
• Vitamin K antagonists

Snippet

Sponsor: Atrial Fibrillation Network | Conditions: Atrial Fibrillation, End-stage Kidney Disease | Phase 3 | Status: COMPLETED